Institute of Engineering Innovation, School of Engineering, The University of Tokyo, Tokyo, Japan;
Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan.
In Vivo. 2021 Jan-Feb;35(1):239-248. doi: 10.21873/invivo.12252.
BACKGROUND/AIM: A mixture of anticancer agents and iodized poppy seed oil (IPSO) has been widely used for intra-arterial chemotherapy of hepatocellular carcinoma. However, the anticancer agents can easily separate from IPSO, so the therapeutic potential is limited. We developed epirubicin-entrapped water-in-oil-in-water emulsion (WOW-Epi) using a double-membrane emulsification technique.
We delivered WOW-Epi through a hepatic arterial injection to VX2 hepatic tumor rabbit model (1.2 mg/kg).
VX2 tumor growth was selectively suppressed in the WOW-Epi-treated group compared with the control treated groups. The accumulation of WOW in nearby cancer cells was confirmed via electron-microscopy. Endocytosis seemed to be the mechanism underlying the uptake of WOW.
WOW-Epi led to tumour growth suppression in vivo. WOW does not cause toxicity to arterial vessels. WOW-Epi will be hopefully used for repeated intra-arterial chemotherapy to HCC patients in the near future.
背景/目的：抗癌药物和碘化罂粟籽油（IPSO）的混合物已被广泛用于肝癌的动脉内化疗。然而，抗癌药物很容易从 IPSO 中分离出来，因此治疗潜力有限。我们使用双膜乳化技术开发了表阿霉素包封的油包水乳状液（WOW-Epi）。
我们通过肝动脉注射将 WOW-Epi 递送至 VX2 肝肿瘤兔模型（1.2 mg/kg）。
与对照组相比，WOW-Epi 处理组的 VX2 肿瘤生长受到选择性抑制。通过电子显微镜证实 WOW 在附近癌细胞中的积累。内吞作用似乎是 WOW 摄取的机制。
WOW-Epi 导致体内肿瘤生长抑制。WOW 不会对动脉血管造成毒性。WOW-Epi 有望在不久的将来用于 HCC 患者的重复动脉内化疗。
